GeparSixto
GeparSixto showed that adding carboplatin to chemotherapy given before surgery made triple-negative breast tumours disappear completely far more often, and in longer follow-up cut relapses, which put platinum into the standard neoadjuvant regimen for this type.
Overview
GeparSixto randomised 595 women with early triple-negative or HER2-positive breast cancer to 18 weeks of weekly paclitaxel and non-pegylated liposomal doxorubicin, with bevacizumab for triple-negative and trastuzumab plus lapatinib for HER2-positive disease, with or without weekly carboplatin. The primary endpoint was pathological complete response.
Carboplatin increased the pathological complete response rate in triple-negative disease, and in longer follow-up improved disease-free survival in that group, but did not help HER2-positive disease and added haematological toxicity. Together with CALGB 40603 and later BrighTNess it established carboplatin as part of neoadjuvant chemotherapy for triple-negative breast cancer, the backbone that KEYNOTE-522 then added pembrolizumab to.
Similar pages
not linked directly; found by shared links- TrialBrighTNess
Shares Early triple-negative breast cancer, Doxorubicin, Paclitaxel / nab-paclitaxel, Carboplatin and the tag subtype-trials.
- TrialATEMPT
Shares Breast cancer (all types), Trastuzumab, Paclitaxel / nab-paclitaxel and the tag subtype-trials.
- TrialNALA
Shares Lapatinib, Breast cancer (all types) and the tag subtype-trials.
- TrialHERACLES
Shares Lapatinib, Trastuzumab and the tag subtype-trials.
- TrialPATINA
Shares Breast cancer (all types), Trastuzumab and the tag subtype-trials.
- TrialKEYNOTE-407
Shares Paclitaxel / nab-paclitaxel, Carboplatin and the tag subtype-trials.
- TrialESOPEC
Shares Paclitaxel / nab-paclitaxel, Carboplatin and the tag subtype-trials.
- TrialTAM-01
Shares Breast cancer (all types) and the tag subtype-trials.